Walking the VLDL tightrope in cardiometabolic diseases. Trends Endocrinol Metab 2025 Mar;36(3):278-291
Date
08/28/2024Pubmed ID
39191606Pubmed Central ID
PMC11861388DOI
10.1016/j.tem.2024.07.020Scopus ID
2-s2.0-85202045237 (requires institutional sign-in at Scopus site)Abstract
Very-low-density lipoprotein (VLDL), a triglyceride-rich lipoprotein secreted by hepatocytes, is pivotal for supplying peripheral tissues with fatty acids for energy production. As if walking on a tightrope, perturbations in the balance of VLDL metabolism contribute to cardiometabolic dysfunction, promoting pathologies such as cardiovascular disease (CVD) or metabolic dysfunction-associated steatotic liver disease (MASLD). Despite the advent of lipid-lowering therapies, including statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, risks for cardiovascular events persist. With limitations to currently available CVD therapeutics and no US Food and Drug Administration (FDA)-approved treatment for MASLD, this review summarizes the current understanding of VLDL metabolism that sheds light on novel therapeutic avenues to pursue for cardiometabolic disorders.
Author List
Kim M, Zheng ZAuthor
Ze Zheng PhD Associate Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsCardiovascular Diseases
Fatty Liver
Humans
Lipoproteins, VLDL
Metabolic Diseases
